<DOC>
	<DOCNO>NCT00750152</DOCNO>
	<brief_summary>A research study compare safety effectiveness investigational medication call NAFT-500 placebo ( active treatment ) , use subject tinea cruris , also know jock itch .</brief_summary>
	<brief_title>Multicenter Study Safety Efficacy NAFT-500 Tinea Cruris</brief_title>
	<detailed_description>To evaluate efficacy safety NAFT-500 , apply daily 2 week , compare placebo treatment subject potassium hydroxide ( KOH ) culture positive symptomatic tinea cruris .</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<criteria>1. Review sign statement Informed Consent HIPAA authorization . 2 . Males nonpregnant female â‰¥12 year age , race sex . Females childbearing potential must negative urine pregnancy test . 3 . For minor ( less 18 year ) , parent/legal guardian must complete informed consent process AND subject must complete assent process sign appropriate form ( age appropriate ) . 4 . Presence tinea cruris characterized clinical evidence tinea infection ( least moderate erythema , moderate scaling , mild pruritus ) confirm sign symptom . 5 . KOH positive culture positive baseline skin scraping obtain site severely affect representative site overall severity . 6 . Subjects must good health free clinically significant disease might interfere study evaluation . 7 . Subjects must able understand requirement study willing comply study requirement . 1 . A lifethreatening condition ( ex . autoimmune deficiency syndrome , cancer , unstable angina , myocardial infarction ) within last 6 month . 2 . Subjects abnormal finding physical laboratory consider investigator clinically important indicative condition might complicate interpretation study result . 3 . Subjects know hypersensitivity study medication component . 4 . Subjects recent history currently know abuse alcohol drug . 5 . Uncontrolled diabetes mellitus . 6 . Hemodialysis chronic ambulatory peritoneal dialysis therapy . 7 . Current diagnosis immunocompromising condition . 8 . Atopic contact dermatitis . 9 . Severe dermatophytoses , mucocutaneous candidiasis , bacterial skin infection . 10 . Female subject pregnant lactating , use agree use acceptable form contraception study , intend become pregnant study ( female surgically sterilize post menopausal least 2 year consider childbearing potential ) . For purpose study , acceptable form birth control include : oral contraceptive , contraceptive patches/implants , double barrier method ( e.g. , use condom spermicide ) , IUD , abstinence second acceptable method subject become sexually active . 11 . Subjects use follow medication : Topical antifungal therapy , powder topical corticosteroid apply within 14 day prior randomization . Terbinafine , butenafine , naftifine ( topical ) within 30 day prior randomization . Oral antifungal therapy within 3 month randomization ( 8 month oral terbinafine ) . Systemic antibiotic corticosteroid treatment within 30 day randomization . Any significant treatment , except hormonal contraception multivitamin , discretion investigator would interfere study treatment . Investigational drug/ device within 30 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>tinea cruris</keyword>
	<keyword>jock itch</keyword>
</DOC>